Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area
- 20 March 2014
- journal article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 29 (4), 820-829
- https://doi.org/10.1111/jgh.12470
Abstract
To evaluate the clinical outcomes of patients with hepatocellular carcinoma (HCC) and compare the findings with that of a previous cohort. Overall, 1972 HCC patients diagnosed and treated at the National Cancer Center, Korea between 2004 and 2009 were enrolled. The data of this cohort were compared with those of a previous cohort (2000-2003) from the same institution. In all (mean age, 56.4 years; 1642 men), 74.6% was hepatitis B virus (HBV) positive, 81.6% were Child-Pugh (CP) class A, and 64.4% was Barcelona Clinic Liver Cancer (BCLC) stage C. The modified Union for International Cancer Control (mUICC) stage I, II, III, IVa, and IVb was found in 8.9%, 29.6%, 24.8%, 23.1%, and 13.6% patients, respectively. The most common initial treatment was transarterial chemotherapy (58.3%), followed by resection (18.6%). The 5-year survival rate of BCLC stage 0, A, B, and C were 79.6%, 67.2%, 33.9%, and 17.1%, respectively. The performance status, BCLC stage, mUICC stage, CP class, model for end-stage liver disease score, tumor characteristics, portal vein tumor invasion, and serum alpha-fetoprotein level proved to be independent prognostic variables. Overall survival in the present cohort was better than that in the previous cohort (hazard ratio, 0.829; 95% confidence interval, 0.754-0.912), especially for advanced HCC patients with HBV-positive status. This cohort study provides valuable insights into the characteristics of HCC in Korean patients. Our findings may help develop clinical trials, treatment strategies, and prognosis systems for HCC patients in HBV-endemic areas.Keywords
Funding Information
- National Cancer Center, Korea (#1110050)
This publication has 22 references indexed in Scilit:
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2012
- Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2009Cancer Research and Treatment, 2012
- Model to estimate survival in ambulatory patients with hepatocellular carcinomaHepatology, 2012
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Practice guidelines for management of hepatocellular carcinoma 2009The Korean Journal of Hepatology, 2009
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Epidemiology of Hepatocellular Carcinoma in Japan and KoreaOncology, 2008
- Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus–endemic areaJournal of Gastroenterology and Hepatology, 2007
- Five-year Survival Analysis of a Cohort of Hepatocellular Carcinoma Patients Who Treated at the National Cancer Center, KoreaThe Korean Journal of Hepatology, 2007
- Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis.Hepatology Research, 2002